contextflow
contextflow is a Vienna-based medical AI company that develops CE-marked deep-learning software for chest CT analysis, helping radiologists detect, quantify, and manage lung cancer, lung diseases, and incidental pulmonary embolism directly within their PACS workflow.
- Company typePrivate
- Founded2016
- HeadquartersVienna, Austria
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What contextflow does
contextflow GmbH is a Vienna-based medical AI company, spun out in July 2016 from the Medical University of Vienna, TU Wien, and the European KHRESMOI research project, that builds deep-learning software for chest CT analysis used by radiologists in hospitals and imaging centers. Its AI Solution Suite is anchored by ADVANCE Chest CT (CE Marked, UKCA marked), which performs nodule detection and quantification, longitudinal tracking, quantitative lung tissue analysis, and qualitative recognition of 19 image patterns, supplemented by a 3D image-based similarity search engine (SEARCH), an automated triage module (TRIAGE), and bundled CE-marked modules for malignancy scoring (RevealAI-Lung from RevealDx) and incidental pulmonary embolism detection (CINA-iPE from Avicenna). The technology is trained on a curated knowledge base of 8,000+ clinical lung CT scans and operates natively inside hospital PACS environments including Sectra, Neologica LogiPACS, and the Blackford AI platform.
The company sells primarily via annual subscription or on-premise software licenses priced per installation location, with quote-based enterprise pricing reflecting institution size, deployment type (cloud vs on-premise), and feature modules selected. Its go-to-market combines direct enterprise field sales to radiology departments, channel partnerships (Blackford/Bayer, Neologica, Curagita, Mint Medical, Collective Minds Radiology), and event-driven demand generation via major radiology conferences and webinar series. End customers include academic medical centers (Erasmus MC, University Medical Center Freiburg, Medical University of Innsbruck, Leiden UMC, Vienna General Hospital), large hospital networks (Imapôle Lyon-Villeurbanne processing 170,000 chest CTs per year, NHS SW London Imaging Network, Providence Little Company of Mary Medical Centers), and pharmaceutical companies using quantitative imaging for clinical trials. The company holds ISO 13485:2016, EU MDR CE Marking, and UKCA, with FDA 510(k) pursued via the announced June 2026 acquisition by Australia's 4DMedical, under which contextflow CEO Markus Holzer will lead the combined entity's European operations as General Manager.
contextflow firmographics
Firmographics- Name
- contextflow
- Legal name
- contextflow GmbH
- Website
- https://contextflow.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- contextflow is a Vienna-based medical AI company that develops CE-marked deep-learning software for chest CT analysis, helping radiologists detect, quantify, and manage lung cancer, lung diseases, and incidental pulmonary embolism directly within their PACS workflow.
- Ownership category
- akta.pro rank
contextflow industry classification
Industry- Product category
- Radiology AI Software
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)
- akta.pro secondary industries
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging) (HLACABAI), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where contextflow is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Offices2 records
Markets served
contextflow business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Software License and Subscription: Non-exclusive, non-transferable software licenses delivered as SaaS or on-premise deployments. Licensed per installation location with pricing based on usage scope and institutional size.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital deployment |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels9 records
contextflow product offering
Product offeringCore offering
contextflow develops and sells an AI Solution Suite for chest CT analysis used by radiologists to detect, quantify, and manage lung cancer, interstitial lung disease, COPD, and incidental pulmonary embolism. The suite is anchored by the CE-marked ADVANCE Chest CT product, which adds RevealAI-Lung malignancy scoring (from RevealDx) and CINA-iPE (from Avicenna) as integrated modules, and is delivered as SaaS or on-premise software licensed to hospitals, PACS vendors, and pharmaceutical companies.
Product overview
contextflow offers an AI Solution Suite for chest CT analysis consisting of well-integrated tools to help radiologists detect, quantify, and manage lung cancer, lung diseases, and incidental pulmonary embolism. The core product is ADVANCE Chest CT (CE Marked), which provides comprehensive computer-aided detection support including nodule detection, lung tissue analysis, and 19 disease pattern recognition. This core platform integrates with RevealAI-Lung (from RevealDx) for malignancy scoring and CINA-iPE (from Avicenna) for incidental pulmonary embolism detection, all CE Marked. The suite is available directly to radiologists and through enterprise AI platform partners like Blackford, and integrates natively into PACS systems including Sectra, Neologica LogiPACS, and others. contextflow also collaborates with Mint Medical on Germany's upcoming lung cancer screening program.
Differentiator
Problem solved
Functional benefit
Products and services
- ADVANCE Chest CT Comprehensive computer-aided detection support for suspected lung cancer, ILD, and COPD on chest CT. Features nodule detection and quantification, nodule tracking over time, quantitative lung tissue analysis, and qualitative analysis of 19 image patterns plus reference cases and differential diagnosis information. CE Marked and available for clinical use in Europe under EU MDR 2017/745. Sold to radiologists, hospitals, PACS vendors, and pharmaceutical companies.
- RevealAI-Lung Malignancy scoring solution from RevealDx distributed as part of contextflow's AI Solution Suite, producing a Malignancy Similarity Index to assist radiologists in making follow-up recommendations for lung cancer diagnosis. Aims to reduce unnecessary procedures and detect lung cancer up to one year sooner. CE Marked.
- CINA-iPE Incidental pulmonary embolism detection tool from Avicenna, distributed as part of contextflow's AI Solution Suite to ensure radiologists do not miss pulmonary embolism findings on chest CT. CE Marked.
Quantifiable outcome
- Average report reading time reduced 31% in clinical study with Medical University of Vienna
- +1 more outcomes
Companies that use contextflow
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
contextflow technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability7 records
Feature6 records
contextflow partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core, major and minor.
- 4DMedicalcore4DMedical announced acquisition of contextflow to expand AI-driven lung imaging capabilities in Europe. The all-share transaction combines cash, shares, and performance-based options, providing 4DMedical with CE-marked products, established customer relationships, European reimbursement pathways, and access to the European respiratory and thoracic imaging market. contextflow CEO Markus Holzer will serve as General Manager of Europe post-acquisition. The combined entity plans to expand beyond functional lung imaging into AI-assisted lung cancer screening.
- Mint MedicalmajorCollaboration on lung cancer screening webinar series in Germany. Contextflow and Mint Medical developed a solution to ensure efficient and consistent reporting within lung cancer screening guidelines as Germany's nationwide LCS program launches.
- VUNOcorePartnership with Korean imaging AI firm VUNO to advance cardiac arrest prediction solution (VUNO Med-DeepCARS) in Europe. contextflow contributes its experience with European reimbursement listing for imaging AI technologies. The three-party MOU with Mesalvo enables system integration, clinical validation, and reimbursement pathways to help DeepCARS adoption in European hospitals.
- MesalvocoreGerman HIS provider supplying hospital information systems across Germany and other European countries. Plans to integrate DeepCARS with electronic medical record and data platforms. Partnership enables access to over 900 hospitals for VUNO's DeepCARS solution.
- CuragitamajorPartnership to improve lung cancer and lung disease diagnostics in Germany through collaboration on chest imaging analysis solutions.
- UZ LeuvenmajorPilot collaboration with University Hospitals Leuven to advance chest imaging analysis, leveraging academic medical center expertise in radiology workflows.
- NeologicamajorCommercial partnership to integrate contextflow ADVANCE Chest CT into Neologica's LogiPACS, bringing comprehensive chest CT support to Neologica's radiology customer base. Founded in 2002, Neologica develops advanced medical imaging software solutions.
- BlackfordcoreCommercial partnership to bring contextflow's ADVANCE Chest CT solution to healthcare providers through Blackford's strategic AI platform. Integration with Blackford's enterprise AI platform provides access to extensive portfolio of medical AI solutions designed to drive clinical efficiency and improve patient outcomes. Blackford was subsequently acquired by Bayer.
- MedexprimminorPartnership to indicate treatment effectiveness and predict disease progression in non-small cell lung cancer (NSCLC) using quantitative imaging analysis.
- Medical University of ViennacoreCore academic founding partner and spin-off origin. Provides clinical data, research collaboration, and scientific validation for AI development. Home to Computational Image Analysis and Radiology Lab (CIR) led by Georg Langs.
- Technical University of Vienna (TU Wien)coreAcademic founding partner providing technical expertise in computer vision, machine learning, and data intelligence research.
- University of CambridgemajorResearch partnership with prestigious international academic institution for advanced AI research in medical imaging.
- Freyr Life SciencesminorSwiss representative office at Bahnhofplatz, CH-6300 Zug for regulatory and market access support in Switzerland.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
contextflow competitors and assessment
Company assessmentDirect peers
- Qure.ai: AI company providing chest X-ray and CT interpretation algorithms including lung nodule and lung disease detection. Targets the same radiology customer base globally with FDA-cleared and CE-marked products.
- Annalise.ai: Comprehensive radiology AI platform covering chest CT findings among other modalities. Comparable as a deep learning radiology decision-support vendor with broad pattern recognition capabilities targeting enterprise radiology customers.
- Aidoc: Israel-based AI radiology platform offering triage and detection algorithms across multiple modalities including chest CT. Directly comparable as a vendor selling AI-powered imaging analysis tools to hospital radiology departments with similar enterprise field sales motion.
- Avicenna AI: French medical imaging AI company whose CINA-iPE product is integrated and distributed by contextflow. Direct peer in the AI-powered incidental pulmonary embolism detection space with similar regulatory and commercial profile.
- Arterys (Tempus): Cloud-native radiology AI platform with FDA-cleared chest CT cardiac and lung analysis tools. Comparable as a venture-backed radiology AI vendor targeting enterprise imaging customers with PACS-integrated workflow solutions.
- Viz.ai: Enterprise AI imaging platform focused on time-sensitive findings (initially stroke, expanding into other conditions). Comparable as a venture-backed radiology AI company selling workflow-integrated detection tools to hospital systems.
- Riverain Technologies: Specializes in chest imaging AI including ClearRead CT for nodule detection, directly overlapping with contextflow's lung nodule detection and lung disease analysis capabilities. Targets the same radiologist customer base with PACS-integrated solutions.
- RevealDx: Lung cancer malignancy scoring AI whose RevealAI-Lung product is integrated with contextflow's ADVANCE Chest CT. Direct peer in lung nodule risk assessment with overlapping customer base and regulatory pathway.
Broad incumbents
- Siemens Healthineers: Global medical imaging vendor with AI-Rad Companion and other AI imaging offerings natively integrated with their PACS and imaging hardware. Represents the incumbent competitive threat with installed base leverage.
- Blackford Analysis (Bayer): Enterprise AI platform for radiology that distributes contextflow's ADVANCE Chest CT alongside a broader portfolio of medical imaging AI solutions. Acquired by Bayer, providing a broader distribution umbrella for AI imaging applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
contextflow social profiles
Digital presencecontextflow compliance and trust
Trust signalCompliance5 records
contextflow financial estimates
Financial estimateRevenue estimate
Valuation estimate
contextflow leadership team
Management profileNumber of profiles
Profiles11 records
contextflow funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
contextflow M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about contextflow
What does contextflow do?
contextflow develops and sells an AI Solution Suite for chest CT analysis used by radiologists to detect, quantify, and manage lung cancer, interstitial lung disease, COPD, and incidental pulmonary embolism. The suite is anchored by the CE-marked ADVANCE Chest CT product, which adds RevealAI-Lung malignancy scoring (from RevealDx) and CINA-iPE (from Avicenna) as integrated modules, and is delivered as SaaS or on-premise software licensed to hospitals, PACS vendors, and pharmaceutical companies.
Is contextflow a public or private company?
contextflow is a private company. It is classified as venture growth investor backed and is currently operating.
When was contextflow founded?
contextflow was founded in 2016. It employs 11 to 50 people.
Where is contextflow based?
contextflow is headquartered in Vienna, Austria, in the Europe region.
How does contextflow make money?
One revenue line is on record: software License and Subscription.
Who are contextflow's main competitors?
Direct peers on record are Qure.ai, Annalise.ai, Aidoc, Avicenna AI, Arterys (Tempus), Viz.ai, Riverain Technologies and RevealDx. Broad incumbents are Siemens Healthineers and Blackford Analysis (Bayer).
Does contextflow have an API?
No public API is recorded for contextflow.
What industry is contextflow in?
contextflow's product category is Radiology AI Software. Its primary akta.pro industry code is HLACALAD, Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic), with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its NAICS code is 3391 and its SIC code is 7372.